---
title: "MMPOWER-3: Elamipretide Phase 3 Results | Primara Labs"
url: https://www.primaralabs.com/research/trials/mmpower-3
source: Primara Labs, markdown mirror of the HTML page
---

# MMPOWER-3

In MMPOWER-3, a phase 3 trial of elamipretide in adults with genetically confirmed primary mitochondrial myopathy (n=218), neither primary endpoint was met: six-minute walk distance and the total fatigue score did not improve significantly against placebo (Karaa A et al. Neurology 2023 (MMPOWER-3), PubMed 37268435).

Primara Labs sells some of the compounds covered here. Every figure on this page links to its source and the date it was checked.

Updated 24 September 2026

## Results

Neither primary endpoint was met: six-minute walk distance and the total fatigue score did not improve significantly against placebo.

## Side effects reported

MMPOWER-3: The abstract describes elamipretide as well tolerated and gives no adverse event rates by arm.

Design

## Trial design and sources

Compound

Elamipretide

Phase

3

Population

Adults with genetically confirmed primary mitochondrial myopathy

Participants randomised

218

Duration

24 weeks

Primary endpoint

Change from baseline in six-minute walk test distance and in the Primary Mitochondrial Myopathy Symptom Assessment total fatigue score

Estimand

Not stated in the source read

Read out

1 July 2023

The abstract describes elamipretide as well tolerated and gives no adverse event rates by arm. Its authors grade the result as Class I evidence that elamipretide did not improve walking distance or fatigue at 24 weeks compared with placebo.

-   Karaa A et al. Neurology 2023 (MMPOWER-3), PubMed 37268435 [open](https://pubmed.ncbi.nlm.nih.gov/37268435/) · checked 3 November 2026
-   ClinicalTrials.gov NCT03323749 [open](https://clinicaltrials.gov/study/NCT03323749) · checked 3 November 2026
-   Registry: NCT03323749

Questions

## MMPOWER-3, answered

### What did MMPOWER-3 find?

In MMPOWER-3, a phase 3 trial of elamipretide in adults with genetically confirmed primary mitochondrial myopathy (n=218), neither primary endpoint was met: six-minute walk distance and the total fatigue score did not improve significantly against placebo (Karaa A et al. Neurology 2023 (MMPOWER-3), PubMed 37268435).

### What side effects were reported in MMPOWER-3?

MMPOWER-3: The abstract describes elamipretide as well tolerated and gives no adverse event rates by arm.

Related

## More on elamipretide

-   [TAZPOWER](https://www.primaralabs.com/research/trials/tazpower)
-   [Evidence Map: Elamipretide](https://www.primaralabs.com/research/evidence#elamipretide)
-   [SS-31 10mg](https://www.primaralabs.com/marketplace/ss-31)